FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Ultraseal International expands thanks to export success

Ann Arbor, MI 04/23/14 · Ultraseal International, the global leader in solutions to...

Kaigai Lifestyle Properties Announces Addition of a Brazilian Development to its Portfolio

Oakville, ON 04/22/14 · – International real estate advisors, Kaigai Lifestyle Properties,...

The Environmental Impact of Creek Excavation: Where Science and Nature Meet

London, United Kingdom 04/21/14 · Excavation is one of the most important and...

DEA HOLDS ITS EIGHTH PRESCRIPTION DRUG TAKE BACK DAY ON SATURDAY APRIL 26

Washington, D.C. 04/21/14 · -- After collecting more than 1,700 tons of expired,...

3 M's - Making Manners Matter

Windsor, Ontario 04/19/14 · 3 M's Making Manners Matter Getting people to improve...

VHL Developments to Start Phase 2 of 2150Condos Project

Toronto, ON 04/19/14 · VHL Developments is pleased to announce they will...

Zatun Game Studio Releases a List of Tools That Aid in iPhone Development

Ahmedabad, Gujarat, India 04/18/14 · Zatun Game Studio, a leading cross-platform video game...

Miami Boom Signals First Rating Increase Since 2004: Muni Credit

Miami, Florida 04/18/14 · Record demand from international investors is boosting prices...

Canadian actor/producer Corey Large presents the drug drama ‘Kid Cannabis’ out April 18

Los Angeles/Vancouver 04/14/14 ·  For Canadian actor/producer Corey Large, the drug drama...

Newborn Foundation Presents at 13th Design of Medical Devices Conference on Innovation for Developing Nations

MINNEAPOLIS, MN 04/10/14 · - Newborn Foundation co-founder and chairman Annamarie Saarinen...

Uk firms can succeed at exporting, says Ultraseal International

Ann Arbor, MI 04/09/14 · Understanding markets overseas is the key to exporting...

First App Created for General Public by Academy's Sci-Tech Council

Beverly Hills, Calif. 04/07/14 · ACADEMY COLOR PREDICTOR LAUNCHES ON iTUNES –The Academy Color...

Grand Estates Auctions sells highest priced home in five years in Pasco County, Florida.

Charlotte, North Carolina 04/04/14 · Sale achieved at auction sets a new benchmark...